Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Liftoff for the Biotech Launch Pad

    September 20, 2023

    Five things: A biotech IPO, Shannon O’Brien suspension, life sciences philanthropy report

    September 19, 2023

    Machine learning biotech raises $273 million in rare successful late-stage round

    September 15, 2023
    Facebook Twitter Instagram
    Your Biotech
    • Bio Technology

      Liftoff for the Biotech Launch Pad

      September 20, 2023

      Five things: A biotech IPO, Shannon O’Brien suspension, life sciences philanthropy report

      September 19, 2023

      Machine learning biotech raises $273 million in rare successful late-stage round

      September 15, 2023

      Discover the synergy between biotech, medtech and digital health in Ghent, a European technology capital

      September 14, 2023

      Here are five biotech companies in Montreal to keep an eye on

      September 13, 2023
    • Pharmaceutical

      Pharma company owner duped of ₹1.1 crore

      November 11, 2022

      Novavax cuts full-year revenue forecast again amid weak demand

      November 10, 2022

      Aurobindo units recall products in US market for manufacturing issues

      November 9, 2022

      AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

      November 8, 2022

      Trade Spotlight | What should you do with Amara Raja, Sun Pharma Advanced Research, Poly Medicure on Monday?

      November 7, 2022
    Your Biotech
    Home»Pharmaceutical»Healthcare & Pharma
    Pharmaceutical

    Healthcare & Pharma

    yourbiotechBy yourbiotechFebruary 11, 2021Updated:November 11, 2022No Comments1 Min Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Investigational Treatment for Alzheimer Disease Reports Positive Topline Clinical Data

    The investigational therapy BIIB080/IONIS-MAPTRx (Biogen Inc and Ionis Pharmaceuticals) met its number one goal of safety and tolerability in sufferers with slight Alzheimer sickness in a section 1b placebo-managed, more than one ascending dose clinical study, in keeping with a press launch from Biogen. The examine further proven robust time and dose-established decreasing of tau protein in cerebrospinal fluid (CSF) over the route of the 3-month remedy length. These discounts have been sustained over the 6-month post-treatment length.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleCellCarta grows its biomarker capacities for clinical
    preliminaries by adding Olink innovation to its
    worldwide administrations
    Next Article Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021
    yourbiotech
    • Website

    Related Posts

    Pharma company owner duped of ₹1.1 crore

    November 11, 2022

    Novavax cuts full-year revenue forecast again amid weak demand

    November 10, 2022

    Aurobindo units recall products in US market for manufacturing issues

    November 9, 2022

    AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

    November 8, 2022

    Leave A Reply Cancel Reply

    Our Picks

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us
    About Us

    We provide a wide range of customized, integrated B2B and B2C digital marketing services solutions that are ideal for your business.

    We're accepting new partnerships right now.

    Email Us: info@yourmartech.com
    Contact: +1-530-518-1420

    Our Brands
    • Your Martech
    • Your HR Tech
    • Your Fin Tech
    • Your Revenue
    • Your Info Tech
    • Your POS Tech
    • Your Health Tech
    SUBSCRIBE NOW
    Loading
    LinkedIn
    • Privacy Policy
    © 2022 Vigarbiz Inc. Designed by Vigarbiz Media

    Type above and press Enter to search. Press Esc to cancel.